Elsevier

Heart Failure Clinics

Volume 7, Issue 3, July 2011, Pages 333-344
Heart Failure Clinics

Chemotherapy-Associated Cardiotoxicity: How Often Does it Really Occur and How Can it Be Prevented?

https://doi.org/10.1016/j.hfc.2011.03.005Get rights and content

Section snippets

Anthracyclines

Anthracyclines are among the most commonly used chemotherapeutic agents, with antineoplastic activity against a wide variety of tumors. In particular, they represent a cornerstone of chemotherapy for lymphomas, hematologic malignancies, breast carcinomas, and sarcomas.

Almost since the time that anthracycline use began, the presence of a dose-dependent rate of cardiotoxicity has been recognized.1, 2, 3, 4, 5 Early reports examined the levels of clinical cardiotoxicity, usually manifesting as

Anti-HER2 Targeted Therapy: Trastuzumab and Lapatinib

Besides the anthracycline drugs, no other cancer medication has been studied in more detail for left ventricular dysfunction than trastuzumab. Trastuzumab is a monoclonal antibody against HER2, an epidermal growth factor receptor family member overexpressed in 20% to 25% of breast cancers.27 HER2 overexpression/amplification connotes a more aggressive tumor with increased rates of metastasis and mortality.27

In addition to its role in breast cancer, HER2 is an important growth factor receptor in

Preventing cardiotoxicity with coadministration of cardiac medications

Standard medical treatment for heart failure uses similar strategies regardless of the underlying cause of the cardiomyopathy. Although older treatments (digoxin, diuretics) were focused on treating the symptoms of heart failure, therapy over the past 3 decades has increasingly focused on neurohormonal antagonism (eg, β-blockers, angiotensin-converting enzyme inhibitors [ACE-Is], angiotensin II receptor blockers [ARBs], aldosterone antagonists).6 The neurohormonal antagonist strategy focuses on

Definitions of left ventricular dysfunction and heart failure

Much of the confusion regarding how to classify cardiotoxicity manifesting as either asymptomatic drops in LVEF or as symptomatic heart failure is attributable to internal confusion in the consensus criteria. In the current “Common Terminology Criteria for Adverse Events (CTCAE) version 4.0,” the same toxicity is listed under three separate headings, and the definition contradicts each another.54 For example, an individual who experienced an asymptomatic treatment-emergent drop in LVEF from 60%

Summary

With the tremendous growth in effective antineoplastic agents, a concomitant concerning increase has occurred in off-target side effects. Cardiotoxicity, and specifically left ventricular dysfunction, remains the limiting factor for many of these agents, and is the focus of growing research and clinical emphasis.

Ultimately winning the battle to allow patients to safely receive indicated doses of increasingly effective anti-neoplastic therapies will require the following conditions:

  • 1.

    Consistent

First page preview

First page preview
Click to open first page preview

References (54)

  • R.H. Blum et al.

    A new anticancer drug with significant clinical activity

    Ann Intern Med

    (1974)
  • E.A. Lefrak et al.

    A clinicopathologic analysis of adriamycin cardiotoxicity

    Cancer

    (1973)
  • C. Tan et al.

    Adriamycin—an antitumor antibiotic in the treatment of neoplastic diseases

    Cancer

    (1973)
  • D.D. Von Hoff et al.

    Risk factors for doxorubicin-induced congestive heart failure

    Ann Intern Med

    (1979)
  • S.A. Hunt et al.

    ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society

    Circulation

    (2005)
  • S.M. Swain et al.

    Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials

    Cancer

    (2003)
  • E.H. Romond et al.

    Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

    N Engl J Med

    (2005)
  • F.M. Torti et al.

    Cardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial biopsy

    Cancer Res

    (1986)
  • M. Ryberg et al.

    Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer

    J Clin Oncol

    (1998)
  • E.C. van Dalen et al.

    Different anthracycline derivates for reducing cardiotoxicity in cancer patients

    Cochrane Database Syst Rev

    (2006)
  • E.S. Casper et al.

    A prospective randomized trial of adjuvant chemotherapy with bolus versus continuous infusion of doxorubicin in patients with high-grade extremity soft tissue sarcoma and an analysis of prognostic factors

    Cancer

    (1991)
  • E.C. van Dalen et al.

    Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy

    Cochrane Database Syst Rev

    (2006)
  • S.E. Lipshultz et al.

    The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia

    N Engl J Med

    (2004)
  • E.C. van Dalen et al.

    Cardioprotective interventions for cancer patients receiving anthracyclines

    Cochrane Database Syst Rev

    (2005)
  • H. Nakamae et al.

    Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone

    Cancer

    (2005)
  • O. Hequet et al.

    Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults

    J Clin Oncol

    (2004)
  • D.L. Hershman et al.

    Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin’s lymphoma

    J Clin Oncol

    (2008)
  • Cited by (0)

    View full text